XM tillhandahåller inte tjänster till personer bosatta i USA.
S
S

Sage


Nyheter

U.S. Boston Beer Company, Inter Parfums, Netflix

U.S. RESEARCH ROUNDUP-Boston Beer Company, Inter Parfums, Netflix July 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Boston Beer Company, Inter Parfums and Netflix, on Friday. HIGHLIGHTS * Boston Beer Company Inc SAM.N : Piper Sandler cuts PT to $344 from $350 * Inter Parfums Inc IPAR.O : Jefferies raises to buy from hold * Netflix Inc NFLX.O : JP Morgan raises target price to $750 from $650 * Smurfit Westrock SW
C
N
N
P
S
D
E
C
C
E
M

U.S. Nvidia, Qualcomm, Tesla

U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla July 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Nvidia, Qualcomm and Tesla, on Wednesday. HIGHLIGHTS * Brighthouse Financial Inc BHF.O : Jefferies raises to buy from hold * Legalzoom.Com Inc LZ.O : JP Morgan cuts to neutral from overweight * Nvidia Corp NVDA.O : KeyBanc raises target price to $180 * Qualcomm Inc QCOM.O : KeyBanc raises target price to $225 * Tesla
A
A
A
A
A
C
G
M
M
N
P
Q
S
T
A
A
A
C
O
B
T
A
A
A
A
C
G
L
U

U.S. Citigroup, Nike, Tesla

U.S. RESEARCH ROUNDUP-Citigroup, Nike, Tesla June 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Citigroup, Nike and Tesla, on Thursday. HIGHLIGHTS * Bread Financial Holdings Inc BFH.N : Evercore ISI raises to in line from underperform * Citigroup C.N : KBW raises target price to $69 from $66 * Lennar Corp LEN.N : Evercore ISI cuts target price to $237 from $238 * Nike Inc NKE.N : Barclays cuts target price to $1
C
I
M
N
N
S
T
D
F
P
A
A

U.S. STOCKS Affirm, Calavo Growers, Shoals Technologies

BUZZ-U.S. STOCKS ON THE MOVE-Affirm, Calavo Growers, Shoals Technologies Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes slipped on Tuesday as investors turned cautious ahead of a crucial inflation reading and a policy announcement from the Federal Reserve expected this week, although a recovery in Apple's shares helped curtail losses.
A
G
G
J
N
S
R
U
U
S
S
R

U.S. STOCKS Spotify, Affirm, Calavo Growers

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Affirm, Calavo Growers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes declined on Tuesday as caution dampened investor enthusiasm ahead of a crucial inflation reading and a policy announcement from the Federal Reserve expected this week.
A
A
G
J
N
S
R
U
U
S
S
F
R

U.S. STOCKS Sage, General Motors, Viridian

BUZZ-U.S. STOCKS ON THE MOVE-Sage, General Motors, Viridian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was set to open lower on Tuesday, with futures tracking all three major indexes in the red as investors were cautious ahead of crucial inflation data and a policy announcement from the Federal Reserve expected this week.
N
S
R
U
S
R

Futures ease on rate-cut jitters ahead of inflation data, Fed meet

US STOCKS-Futures ease on rate-cut jitters ahead of inflation data, Fed meet For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Eli Lilly up as Alzheimer's drug gets US FDA panel backing Crypto stocks fall as bitcoin hits one-week low GM approves $6 billion share buyback plan Futures lower: Dow 0.31%, S&P 0.22%, Nasdaq 0.23% Updated at 8:16 a.m.
A
A
M
N
S
U
U
U
B

Sage climbs as Huntington's drug found to be safe in mid-stage study

BUZZ-Sage climbs as Huntington's drug found to be safe in mid-stage study ** Shares of Sage Therapeutics SAGE.O rise 1.8% to $11.10 premarket ** Drug developer says its drug, dalzanemdor, was found to be safe in patients with a rare, genetic neurological condition called Huntington's disease in a part of a mid-stage study ** SAGE says the study in
S

Futures slip as investors await Fed meeting, CPI numbers

US STOCKS-Futures slip as investors await Fed meeting, CPI numbers For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Eli Lilly up as Alzheimer's drug gets US FDA panel backing Crypto stocks fall as bitcoin hits one-week low Futures off: Dow 0.44%, S&P 0.33%, Nasdaq 0.33% Updated at 7:06 a.m.
A
N
S
U
U
U
B

Sage Therapeutics says rare disease drug found to be safe in mid-stage study

UPDATE 2-Sage Therapeutics says rare disease drug found to be safe in mid-stage study Updates shares in paragraph 4, adds details on trial in paragraphs 5 & 9, analysts comments in paragraphs 6, 8 & 10 June 11 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday a part of a mid-stage study showed its experimental drug was safe and had some effect in patients with a rare, genetic neurological condition called Huntington's disease.
S

Sage Therapeutics' rare disease drug meets main goal in mid-stage study

Sage Therapeutics' rare disease drug meets main goal in mid-stage study June 11 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday its experimental drug met the main goal of a mid-stage study in patients with a type of rare disease known as Huntington's disease. Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber
S

U.S. Autodesk, McKesson, MicroStrategy

U.S. RESEARCH ROUNDUP-Autodesk, McKesson, MicroStrategy May 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, McKesson and Microstrategy, on Wednesday. HIGHLIGHTS * Analog Devices Inc ADI.O : Raymond James raises target price to $260 from $215 * Autodesk Inc ADSK.O : Baird cuts target price to $289 from $296 * Cencora Inc COR.N : Baird raises target price to $280 from $277 * McKesson Corp MCK.N : Baird rai
A
C
S
A
A
U
D
M
L
M

SAGE Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in March - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.80​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-2.46. The mean expectation of eighteen analysts for the quarter was for a loss of $1.65 per share.
S

U.S. STOCKS Globe Life, EQT, Ribbon Communications

BUZZ-U.S. STOCKS ON THE MOVE-Globe Life, EQT, Ribbon Communications Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes pared early gains to trade lower on Wednesday, as losses in heavyweight tech stocks outweighed positive earnings across several sectors and rising Treasury yields further pressured equities.
A
B
B
G
H
S
T
V
T
U
U
D
E
W
G

U.S. STOCKS MSCI, Globe Life, EQT Corp

BUZZ-U.S. STOCKS ON THE MOVE-MSCI, Globe Life, EQT Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq outpaced Wall Street peers on Wednesday, with Tesla leading gains among megacap stocks after its quarterly results, while upbeat earnings reports across other sectors also offered support.
A
B
B
G
H
S
T
V
T
U
U
E
W
F
G

Sage rises as partner Biogen posts strong Q1 sales of postpartum depression pill

BUZZ-Sage rises as partner Biogen posts strong Q1 sales of postpartum depression pill ** Shares of Sage Therapeutics SAGE.O up 13.1% at $14.65 premarket ** Partner Biogen BIIB.O reports $12 mln in Q1 revenue from post-partum depression pill Zurzuvae ** At least three analysts say that sales of Zurzuvae came in ahead of their expectations ** Jefferi
B
S

SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.65 a share - Earnings Preview

SAGE Therapeutics Inc expected to post a loss of $1.65 a share - Earnings Preview SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on April 25 for the period ending March 31 2024 The Cambridge Massachusetts-based company is expected to report a 71.8% increase in revenue to $5.658 million from $3.29 million a year ago, according to the mean estimate from 17 analysts, based on LSEG data.
S

U.S. Builders Firstsource, Eli Lilly, Northern Trust

U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust April 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Builders Firstsource, Eli Lilly and Northern Trust, on Thursday. HIGHLIGHTS * Alphabet Inc GOOGL.O : Bernstein raises target price to $165 from $160 * Builders Firstsource Inc BLDR.N : Jefferies raises target price to $237 from $226 * Coinbase Global Inc COIN.O : Bernstein raises target price
A
A
C
C
C
C
F
G
J
N
Q
S
A
L
J
A
C

U.S. STOCKS Outset Medical, Interactive Brokers, US energy sector

BUZZ-U.S. STOCKS ON THE MOVE-Outset Medical, Interactive Brokers, US energy sector Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in choppy trading on Wednesday with chip stocks among the top losers, while downbeat earnings reports from some industry majors, including insurer Travelers, added to the losses.
I
S
U
A
J
U
U
U
C

U.S. STOCKS Children's Place, Travelers, First Horizon

BUZZ-U.S. STOCKS ON THE MOVE-Children's Place, Travelers, First Horizon Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on Wednesday, boosted by megacap growth stocks and as corporate results rolled in, while investors awaited commentary from Federal Reserve policymakers for clues on the economy's health.
A
I
S
U
A
A
J
U
U
U



Villkor

Populära tillgångar

Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.

Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.

Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.

Riskvarning: Ditt kapital riskeras. Hävstångsprodukter passar kanske inte alla. Se vår riskinformation.